Tekla Life Sciences Investors Receives Shareholder Approval for New Investment Advisory Agreement with abrdn Inc.

Tekla Life Sciences Investors (HQL) recently announced that its shareholders have approved the new investment advisory agreement with abrdn Inc. This milestone marks an important step forward for the company and its commitment to delivering value to its shareholders.

During the Joint Special Meetings of shareholders, the requisite vote was reached to approve the investment advisory agreement. The agreement with abrdn Inc. is expected to bring several benefits to shareholders, as outlined in the proxy statement. However, it is important to note that the agreement cannot be implemented without the approval of shareholders of all four Funds, including Tekla Healthcare Investors (HQH), Tekla Healthcare Opportunities Fund (THQ), and Tekla World Healthcare Fund (THW).

While Tekla Life Sciences Investors achieved the necessary vote, the Special Meetings for the other Funds were adjourned due to a lack of quorum. The adjourned meetings for Tekla Healthcare Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund are scheduled for October 13, 2023 (HQH) and October 25, 2023 (THQ and THW), both at 9:00 a.m. EDT.

Shareholders who have not yet voted on the Proposal are urged to do so promptly, even if they choose to cast an abstain vote. Reaching the necessary quorum is crucial for the successful implementation of the new investment advisory agreement.

Tekla is an asset manager with a primary focus on healthcare investing. The company’s expertise comes from a diverse team of individuals with advanced degrees in science and business, investing experience, and industry knowledge. For more information about Tekla, please visit their website at www.teklacap.com.

abrdn Inc. is a global investment company that helps clients plan, save, and invest for the future. With a purpose to enable clients to be better investors, abrdn manages and administers £500bn of assets for clients as of December 31, 2022. The company’s Investments business, which manages £376bn on behalf of clients, leverages extensive research, worldwide investment expertise, and local market knowledge to identify investment opportunities. To learn more about abrdn, please visit www.abrdn.com.

Investors are encouraged to vote using the Proxy Card or email with the voting link provided. Voting instructions can also be found in the Proxy Statement available at www.OkapiVote.com/TeklaSpecial. Shareholders requiring voting assistance can contact Okapi Partners, the Funds’ proxy solicitor, at (877) 285-5990.

In conclusion, Tekla Life Sciences Investors has received shareholder approval for the new investment advisory agreement with abrdn Inc. This development highlights the company’s commitment to delivering value to its shareholders and further strengthens its position in the healthcare investing sector.